Where are we going with sentinel nodes mapping in ovarian cancer?
Lymph node involvement is a major predictive indicator in early-stage epithelial ovarian cancer (EOC). There is presently no effective way to determine lymph node involvement other than surgical staging. As a result, traditional ovarian cancer surgery still includes pelvic and paraaortic lymphadenec...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.999749/full |
| _version_ | 1828094621124657152 |
|---|---|
| author | Nirmala Chandralega Kampan Chew Kah Teik Mohammed Nasir Shafiee |
| author_facet | Nirmala Chandralega Kampan Chew Kah Teik Mohammed Nasir Shafiee |
| author_sort | Nirmala Chandralega Kampan |
| collection | DOAJ |
| description | Lymph node involvement is a major predictive indicator in early-stage epithelial ovarian cancer (EOC). There is presently no effective way to determine lymph node involvement other than surgical staging. As a result, traditional ovarian cancer surgery still includes pelvic and paraaortic lymphadenectomy. However, it might be linked to higher blood loss, lengthier operations, and longer hospital stays. The creation of a technique for accurately predicting nodal status without significant lymphadenectomy is thus the subject of ongoing research. Sentinel lymph nodes (SLN) mapping is a routine procedure in oncological surgery and has been proven to be effective and safe in cervical, vulvar, and uterine cancer. On the other hand, SLN mapping is not yet widely accepted and recognized in EOC. A thorough search of the literature was conducted between January 1995 to March 2022, using PubMed and Embase. This review included studies on lymphatic outflow of the ovaries and the sentinel lymph node method. A total of 13 studies involving 212 patients who underwent sentinel lymph node mapping for ovaries were included. Both open and laparoscopic approach are used. The most popular injection site is the ovarian ligaments, and a variety of agents are utilized, although the main markers were, technetium-99m radiocolloid (Tc-99m) or indocyanine green, either alone or in combination. Overall detection rate for SLN in ovaries is 84.5% (interquartile range: 27-100%). We suggest a standardized method for sentinel lymph node mapping in ovarian cancer. The detection rates, characterization and true positive rates of the approach in investigations support further study. The use of ultra-staging is essential for lower-volume metastasis and reproducibility. To ascertain the clinical utility of sentinel node in early ovarian cancer, larger collaborative prospective clinical trials are necessary. |
| first_indexed | 2024-04-11T07:01:58Z |
| format | Article |
| id | doaj.art-1c98b994e8554b20aec07b81e52e54e0 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T07:01:58Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-1c98b994e8554b20aec07b81e52e54e02022-12-22T04:38:39ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-11-011210.3389/fonc.2022.999749999749Where are we going with sentinel nodes mapping in ovarian cancer?Nirmala Chandralega KampanChew Kah TeikMohammed Nasir ShafieeLymph node involvement is a major predictive indicator in early-stage epithelial ovarian cancer (EOC). There is presently no effective way to determine lymph node involvement other than surgical staging. As a result, traditional ovarian cancer surgery still includes pelvic and paraaortic lymphadenectomy. However, it might be linked to higher blood loss, lengthier operations, and longer hospital stays. The creation of a technique for accurately predicting nodal status without significant lymphadenectomy is thus the subject of ongoing research. Sentinel lymph nodes (SLN) mapping is a routine procedure in oncological surgery and has been proven to be effective and safe in cervical, vulvar, and uterine cancer. On the other hand, SLN mapping is not yet widely accepted and recognized in EOC. A thorough search of the literature was conducted between January 1995 to March 2022, using PubMed and Embase. This review included studies on lymphatic outflow of the ovaries and the sentinel lymph node method. A total of 13 studies involving 212 patients who underwent sentinel lymph node mapping for ovaries were included. Both open and laparoscopic approach are used. The most popular injection site is the ovarian ligaments, and a variety of agents are utilized, although the main markers were, technetium-99m radiocolloid (Tc-99m) or indocyanine green, either alone or in combination. Overall detection rate for SLN in ovaries is 84.5% (interquartile range: 27-100%). We suggest a standardized method for sentinel lymph node mapping in ovarian cancer. The detection rates, characterization and true positive rates of the approach in investigations support further study. The use of ultra-staging is essential for lower-volume metastasis and reproducibility. To ascertain the clinical utility of sentinel node in early ovarian cancer, larger collaborative prospective clinical trials are necessary.https://www.frontiersin.org/articles/10.3389/fonc.2022.999749/fullsentinel lymph nodeovarian cancerlymphadenectomylow-volume metastasessentinel lymph node biopsysentinel lymph node mapping |
| spellingShingle | Nirmala Chandralega Kampan Chew Kah Teik Mohammed Nasir Shafiee Where are we going with sentinel nodes mapping in ovarian cancer? Frontiers in Oncology sentinel lymph node ovarian cancer lymphadenectomy low-volume metastases sentinel lymph node biopsy sentinel lymph node mapping |
| title | Where are we going with sentinel nodes mapping in ovarian cancer? |
| title_full | Where are we going with sentinel nodes mapping in ovarian cancer? |
| title_fullStr | Where are we going with sentinel nodes mapping in ovarian cancer? |
| title_full_unstemmed | Where are we going with sentinel nodes mapping in ovarian cancer? |
| title_short | Where are we going with sentinel nodes mapping in ovarian cancer? |
| title_sort | where are we going with sentinel nodes mapping in ovarian cancer |
| topic | sentinel lymph node ovarian cancer lymphadenectomy low-volume metastases sentinel lymph node biopsy sentinel lymph node mapping |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.999749/full |
| work_keys_str_mv | AT nirmalachandralegakampan wherearewegoingwithsentinelnodesmappinginovariancancer AT chewkahteik wherearewegoingwithsentinelnodesmappinginovariancancer AT mohammednasirshafiee wherearewegoingwithsentinelnodesmappinginovariancancer |